207 related articles for article (PubMed ID: 24238043)
1. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
Sherman SK; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
Surgery; 2013 Dec; 154(6):1206-13; discussion 1214. PubMed ID: 24238043
[TBL] [Abstract][Full Text] [Related]
2. GIPR expression in gastric and duodenal neuroendocrine tumors.
Sherman SK; Maxwell JE; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
J Surg Res; 2014 Aug; 190(2):587-93. PubMed ID: 24565507
[TBL] [Abstract][Full Text] [Related]
3. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
Kim JY; Kim J; Kim YI; Yang DH; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
Sci Rep; 2024 Feb; 14(1):4047. PubMed ID: 38374188
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.
Carr JC; Boese EA; Spanheimer PM; Dahdaleh FS; Martin M; Calva D; Schafer B; Thole DM; Braun T; O'Dorisio TM; O'Dorisio MS; Howe JR
Surgery; 2012 Dec; 152(6):998-1007. PubMed ID: 23158174
[TBL] [Abstract][Full Text] [Related]
7. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells.
Watanabe H; Fujishima F; Unno M; Sasano H; Suzuki T
Pathol Res Pract; 2023 Apr; 244():154418. PubMed ID: 36989844
[TBL] [Abstract][Full Text] [Related]
9. Comparative single-cell RNA sequencing (scRNA-seq) reveals liver metastasis-specific targets in a patient with small intestinal neuroendocrine cancer.
Rao M; Oh K; Moffitt R; Thompson P; Li J; Liu J; Sasson A; Georgakis G; Kim J; Choi M; Powers S
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32054662
[TBL] [Abstract][Full Text] [Related]
10. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
[TBL] [Abstract][Full Text] [Related]
11. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors.
Fotouhi O; Zedenius J; Höög A; Juhlin CC
Neuro Endocrinol Lett; 2018 Oct; 39(4):305-309. PubMed ID: 30531706
[TBL] [Abstract][Full Text] [Related]
12. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
Garcia-Carbonero R; Sorbye H; Baudin E; Raymond E; Wiedenmann B; Niederle B; Sedlackova E; Toumpanakis C; Anlauf M; Cwikla JB; Caplin M; O'Toole D; Perren A;
Neuroendocrinology; 2016; 103(2):186-94. PubMed ID: 26731334
[No Abstract] [Full Text] [Related]
13. Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model.
Sharma R; Earla B; Baidoo KE; Zeiger MA; Madigan JP; Escorcia FE; Sadowski SM
Mol Cancer Ther; 2023 Sep; 22(9):1052-1062. PubMed ID: 37487000
[TBL] [Abstract][Full Text] [Related]
14. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
[TBL] [Abstract][Full Text] [Related]
15. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
16. Pathologic Classification of Neuroendocrine Neoplasms.
Klimstra DS
Hematol Oncol Clin North Am; 2016 Feb; 30(1):1-19. PubMed ID: 26614366
[TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors.
Malczewska A; Kidd M; Matar S; Kos-Kudla B; Modlin IM
Neuroendocrinology; 2018; 107(1):73-90. PubMed ID: 29566385
[TBL] [Abstract][Full Text] [Related]
18. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts.
Celinski SA; Fisher WE; Amaya F; Wu YQ; Yao Q; Youker KA; Li M
J Surg Res; 2003 Nov; 115(1):41-7. PubMed ID: 14572771
[TBL] [Abstract][Full Text] [Related]
20. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).
Orgera G; Krokidis M; Cappucci M; Gourtsoyianni S; Tipaldi MA; Hatzidakis A; Rebonato A; Rossi M
Cardiovasc Intervent Radiol; 2015 Feb; 38(1):13-24. PubMed ID: 25366087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
